CLAIMS

1. A composition comprising:
   an effective amount of rifabutin;
   an effective amount of clarithromycin; and
   an effective amount of clofazimine,
for use in the treatment of multiple sclerosis.

2. The composition of claim 1 further comprising an antibiotic selected from the group consisting of daptomycin, clindamycin, rifampicin, erythromycin, oleandomycin, roxithromycin, azithromycin, kanamycin, gentamycin, tobramycin, streptomycin, neomycin, paromomycin, ethambutol, isoniazid, minocyclin, and tetracycline.

3. The composition of claim 1 formulated for oral administration.

4. The composition of claim 1 formulated for intravenous administration.

5. The composition of claim 1 further comprising an absorption enhancer.

6. The composition of claim 1 wherein the clofazimine is dispersed in polyethylene glycol.

7. The composition of claim 1 further comprising an anti-inflammatory agent.

8. Use of an effective amount of rifabutin, clarithromycin, and clofazimine in the preparation of a medicament for the therapeutic and/or prophylactic treatment of multiple sclerosis.

9. The composition of claim 1 for the treatment of remitting-relapsing multiple sclerosis.

10. The composition of claim 1 further comprising Vitamin D.

11. The composition of claim 1 further comprising a cyclin dependent kinase inhibitor.

12. The composition of claim 1 further comprising an activated T-cell transcription inhibitor.

13. The composition of claim 1 wherein, upon administration of the composition to a subject with multiple sclerosis, a reduction in demyelination is observed.

14. The composition of claim 1 wherein, upon administration of the composition to a subject with multiple sclerosis, at least an amelioration of one or more symptoms associated with multiple sclerosis is observable.

15. The composition of claim 7 wherein the anti-inflammatory agent is selected from one or a combination of 5-aminosalicylic acid, azathioprine or methotrexate.

CLAIMS

1. Use of rifabutin, clarithromycin, and clofazimine, in the preparation of a medicament for the therapeutic and/or prophylactic treatment of remitting-relapsing multiple sclerosis.

2. The use of claim 1 wherein the medicament further comprises an antibiotic selected from the group consisting of daptomycin, clindamycin, rifampicin, erythromycin, oleandomycin, roxithromycin, azithromycin, kanamycin, gentamycin, tobramycin, streptomycin, neomycin, paromomycin, ethambutol, isoniazid, minocyclin, and tetracycline.

3. The use of claim 1 wherein the medicament is formulated for oral administration.

4. The use of claim 1 wherein the medicament is formulated for intravenous administration.

5. The use of claim 1 wherein the medicament further comprises an absorption enhancer.

6. The use of claim 1 wherein the clofazimine is dispersed in polyethylene glycol.

7. The use of claim 1 wherein the medicament further comprises an anti-inflammatory agent.

8. Use of rifabutin, clarithromycin, and clofazimine in the preparation of a medicament for the therapeutic and/or prophylactic treatment of multiple sclerosis.

9. The use of claim 1 wherein the medicament further comprises Vitamin D.

10. The use of claim 1 wherein the medicament further comprises a cyclin dependent kinase inhibitor.

11. The use of claim 1 wherein the medicament further comprises an activated T-cell transcription inhibitor.

12. The use of claim 8 wherein, upon administration of the medicament to a subject with multiple sclerosis, a reduction in demyelination is observed.

13. The use of claim 8 wherein, upon administration of the medicament to a subject with multiple sclerosis, at least an amelioration of one or more symptoms associated with multiple sclerosis is observable.

14. The use of claim 7 wherein the anti-inflammatory agent is selected from one or a combination of 5-aminosalicylic acid, azathioprine or methotrexate.

15. The use of claim 8 wherein the medicament further comprises an antibiotic selected from the group consisting of daptomycin, clindamycin, rifampicin, erythromycin, oleandomycin, roxithromycin, azithromycin, kanamycin, gentamycin, tobramycin, streptomycin, neomycin, paromomycin, ethambutol, isoniazid, minocyclin, and tetracycline.

16. The use of claim 8 wherein the medicament is formulated for oral administration.

17. The use of claim 8 wherein the medicament is formulated for intravenous administration.

18. The use of claim 8 wherein the medicament further comprises an absorption enhancer.

19. The use of claim 8 wherein the clofazimine is dispersed in polyethylene glycol.

20. The use of claim 8 wherein the medicament further comprises an anti-inflammatory agent.

21. The use of claim 8 wherein the medicament further comprises Vitamin D.

22. The use of claim 8 wherein the medicament further comprises a cyclin dependent kinase inhibitor.

23. The use of claim 8 wherein the medicament further comprises an activated T-cell transcription inhibitor.

24. The use of claim 21 wherein the anti-inflammatory agent is selected from one or a combination of 5-aminosalicylic acid, azathioprine or methotrexate.